The company is currently scaling its peptide production capacity, aiming for a monthly output of 800,000 vials by early autumn. With gross margins projected between 60% and 80%, the firm is positioning itself within the sports medicine market to address supply shortages for pharma-grade, cGMP-manufactured peptides. Management points to recent industry consolidation, such as the acquisition of PolyPeptide Group AG, as evidence of the high demand for licensed manufacturing capacity.
Simultaneously, the development of VectorMist, a device for perioperative pain management in laparoscopic surgery, remains on schedule. The company intends to submit a 510(k) filing to the FDA, with potential revenue generation targeted before the close of 2026. To support these commercial launches, the firm has assembled a specialized sales team focused on orthopedic and sports medicine distribution channels. Leadership will outline these growth strategies during an inaugural investor Q&A session scheduled for July 28.
Comments (0)
No comments yet. Be the first!